Melanoma antigen family A2B (MAGEA2B)

Melanoma antigen family A2B (MAGEA2B) is a member of the MAGE-A subfamily of cancer/testis antigens found at Xq28, sharing high sequence homology (50-80%) with other MAGEA genes. These proteins modulate cellular stress responses by interacting with the p53 tumor suppressor pathway, specifically forming complexes with p53 and recruiting histone deacetylase 3 (HDAC3) to downregulate p53 activity and promote cell survival. MAGEA2 can also stabilize inhibitors of p53 by inhibiting MDM2 E3 ligase activity. Overexpression of MAGEA2 (and by extension, its highly similar copies, such as MAGEA2B) in cancers such as melanoma, breast, lung, colon, multiple myeloma, ovarian, and others confers resistance to chemotherapy and correlates with poor clinical prognosis. The gene is tightly regulated by epigenetic methylation, usually silenced in normal tissues but aberrantly activated in tumors. MAGEA2B’s biological role, mechanisms, and therapeutic utility are inferred from the large body of work on MAGEA2 and the MAGE-A family, rather than any unique properties of MAGEA2B itself, as it is rarely the focus of specific studies and may function identically to MAGEA2.

Other names

MAGEA2MAGE2MAGEA2ACT1.2MGC16973Cancer/testis antigen 1.2MAGE-2 antigenMelanoma-associated antigen 2

Immunotherapy (T cell recognition of MAGEA family antigens; experimental); Epigenetic modulation (demethylating agents induce expression; not directly targeting MAGEA2B)